Diffuse Large B Cell Lymphoma Recurrent clinical trials

Explore recruiting diffuse large b cell lymphoma recurrent clinical trials.

Recruiting diffuse large b cell lymphoma recurrent studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Diffuse Large B Cell Lymphoma Recurrent trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase I/II Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Patients with Diffuse Large B-Cell Lymphoma following First-Line Immunochemotherapy and as Monotherapy or In Combination With Polatuzumab Vedotin in Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Spain, Poland

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Randomized, Open-Label, Phase 2 Study Evaluating Lymphodepletion With Fludarabine, Cyclophosphamide, And ALLO-647, Vs. Fludarabine And Cyclophosphamide Alone, In Subjects With Relapsed/Refractory Large B-Cell Lymphoma (LBCL) Receiving ALLO-501A Allogeneic CAR T Cell Therapy

Belgium, Germany, Austria

Therapeutic exploratory (Phase II) EU CTIS Study details

Double-T - Improving outcomes in high-risk 2nd line relapsed/refractory Large B-Cell Lymphoma patients eligible for CAR-T-cell therapy with a Glofitamab-based induction and consolidation concept

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A first-in-human, open-label, clinical study to assess the safety, tolerability, and activity of OT-C001 (amplified/activated allogenic natural killer cells) in patients with relapsed/refractory diffuse large B-cell lymphoma

France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Modular Phase II, Single-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Surovatamig (AZD0486) in Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (SOUNDTRACK-B) )

Germany, Spain, Denmark, Italy, Sweden, France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Subjects with Relapsed/Refractory Large B Cell Lymphoma (LBCL).

Italy, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Diffuse Large B Cell Lymphoma Recurrent trials by city

Diffuse Large B Cell Lymphoma Recurrent in Toronto Diffuse Large B Cell Lymphoma Recurrent in Vancouver Diffuse Large B Cell Lymphoma Recurrent in Montreal Diffuse Large B Cell Lymphoma Recurrent in Calgary Diffuse Large B Cell Lymphoma Recurrent in Edmonton Diffuse Large B Cell Lymphoma Recurrent in Ottawa Diffuse Large B Cell Lymphoma Recurrent in Winnipeg Diffuse Large B Cell Lymphoma Recurrent in Quebec City Diffuse Large B Cell Lymphoma Recurrent in Hamilton Diffuse Large B Cell Lymphoma Recurrent in Kitchener Diffuse Large B Cell Lymphoma Recurrent in London Diffuse Large B Cell Lymphoma Recurrent in Halifax Diffuse Large B Cell Lymphoma Recurrent in New York Diffuse Large B Cell Lymphoma Recurrent in Los Angeles Diffuse Large B Cell Lymphoma Recurrent in Chicago Diffuse Large B Cell Lymphoma Recurrent in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease